PMET Demonstrates >97% Caesium Extraction from Pollucite Concentrate

PMET reports bench-scale caesium extraction results from pollucite concentrate, achieving >97–98% Cs recovery into solution using sulphuric acid leaching at up to 120°C, while successfully removing key impurities (e.g., aluminum) with negligible Cs losses. The company is running parallel testwork with Koch Technology Solutions, where Phase 1 preliminary results show selective, high loading-factor Cs recovery using Koch’s proprietary flow sheet (leveraging both synthetic and live pregnant leaching solutions). Next steps target gram-scale production of high-purity caesium salts/carbonates (Cs-sulphate, Cs-carbonate, Cs-formate) and potentially Rb-carbonate, with expected further results around Q4 2026 alongside a broader PEA and CV5 feasibility work scheduled for Q4 2026.

Analysis

This is incrementally bullish for PMET, but mostly as a de-risking event rather than a monetization event. Bench-scale recovery above 97% tells the market the caesium circuit is not obviously broken; it does not yet prove recoverable dollars per tonne, reagent intensity, product spec, or whether downstream qualification will support premium pricing. In our frame, the near-term effect is a modest reduction in technical discount on the CV13 optionality, while the real valuation debate remains whether caesium is a meaningful second-order NPV driver or simply a nice byproduct credit.

The key second-order read-through is that PMET is trying to turn a lithium/tantalum project into a multi-commodity platform, which can lift the multiple only if investors believe the caesium stream lowers unit costs or funds capex. That can help sentiment versus other junior lithium names, but it also raises execution complexity: more circuits, more QA/QC, more permitting surface area, and more ways for the PEA to disappoint. If the Q4 2026 PEA shows caesium adds only a small fraction of project value, the current enthusiasm will likely fade quickly.

Contrarian view: the market may be overweighting the phrase "world’s largest" and underweighting the fact that specialty-chemical optionality is only valuable once reproducible at scale with a bankable off-take path. The tradeable catalyst path is not this release; it is the PEA and any proof-of-concept product samples. Falsifiers are simple: if the PEA lands with de minimis caesium contribution, materially higher capex/opex, or no clear route to gram-scale product qualification, the caesium thesis should be discounted back to zero.

Key Decisions for Investors

• PMET.TO / PMETF: Tactical long only on post-news weakness, not strength. Use the current de-risking as a setup for a 1-3 month trade into the Q4 2026 PEA; risk/reward is acceptable only if the stock retraces 5-10% and holds the pre-release range.
• PMET.TO: Prefer a call spread over outright equity if you want exposure to PEA optionality. Structure for limited premium at risk into Q4 2026, since the upside is a re-rating on caesium monetization while downside is likely if the PEA shows the byproduct is immaterial.
• Relative value: long PMET.TO vs. a basket of pure-play junior lithium developers with no byproduct optionality. The thesis is that even a small caesium credit can support a better project narrative and financing optics than single-commodity peers, but only until the PEA forces a valuation reset.
• Watch item, not trade: if management discloses gram-scale Cs-sulfate/Cs-carbonate/Cs-formate and third-party product specs by Q4 2026, reassess for a higher-conviction long. If that milestone slips, treat the current move as promotional and fade the strength.